Nanopharm and Gateway Analytical operations are complementary to the group’s pharma service offerings
AptarGroup has acquired two leading pharmaceutical services companies, Nanopharm and Gateway Analytical. The combined enterprise value of the deal is approximately US$50 million.
The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.
Both acquisitions bring complementary, value-added and differentiated analytical, testing and development services for all stages of drug development and commercialisation. The expanded services platform will enable Aptar to collaborate earlier with customers to support their complex drug formulations and delivery requirements as they face increasingly competitive and regulated markets.
Nanopharm, located in Newport, UK, is a science-driven, leading provider of orally inhaled and nasal drug product design and development services.
Gateway Analytical, located in Gibsonia, PA, provides industry-leading particulate detection and predictive analytical services to customers developing injectable medicines.
The companies’ results will be included in the Pharma segment and the transactions are not expected to be dilutive to Aptar’s earnings in 2019.
Gael Touya, President of Aptar Pharma, said: “This enables us to participate in a broader spectrum of the pre-clinical, clinical trial and market launch phases of drug development.”
Stephan Tanda, President and CEO, said: “These strategic investments further strengthen our best in class pharma business and increase our ability to add to our long-term growth pipeline by adding depth to our service offerings.
Tanda continued to say that the expertise of these two established companies is complementary to current operations.